In the metastatic non-oncogene addicted NSCLC group, the PD1/PD-L1 axis blockade has been introduced as monotherapy or in combination with chemotherapy in naïve patients according to the tumor expression of PD-L1 defined as Tumor Proportion Score (TPS). This evidence concerns the gene CD274 and non-small cell lung carcinoma.